Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors

被引：100
作者：
Kwekkeboom, Dik J. [1 ]
Krenning, Eric P. [1 ]
机构：
[1] Univ Med Ctr, Erasmus MC, Dept Nucl Med, NL-3015 CE Rotterdam, Netherlands
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2016年 / 30卷 / 01期
关键词：
Neuroendocrine tumor; Carcinoid; Radionuclide therapy; PRRT; Treatment; RADIOLABELED SOMATOSTATIN ANALOG; PHASE-I; RADIOPEPTIDE LU-177-OCTREOTATE; CARCINOID-SYNDROME; SALVAGE THERAPY; COMBINATION; TOXICITY; SURVIVAL; Y-90-DOTATOC; CAPECITABINE;
D O I：
10.1016/j.hoc.2015.09.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Peptide receptor radionuclide therapy (PRRT) is a promising new treatment modality for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors patients. Most studies report objective response rates in 15% to 35% of patients. Progression-free (PFS) and overall survival (OS) compare favorably with that for somatostatin analogues, chemotherapy, or newer, "targeted" therapies. Prospective, randomized data regarding the potential PFS and OS benefit of PRRT compared with standard therapies is anticipated.
引用
收藏
页码：179 / +
页数：15
相关论文
共 53 条
  • [1] Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
    Anthony, LB
    Woltering, EA
    Espenan, GD
    Cronin, MD
    Maloney, TJ
    McCarthy, KE
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2002, 32 (02) : 123 - 132
  • [2] Balon HR, 2001, J NUCL MED, V42, P1134
  • [3] Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion:: a phase I study
    Bodei, L
    Cremonesi, M
    Zoboli, S
    Grana, C
    Bartolomei, M
    Rocca, P
    Caracciolo, M
    Mäcke, HR
    Chinol, M
    Paganelli, G
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (02) : 207 - 216
  • [4] Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors
    Bodei, Lisa
    Cremonesi, Marta
    Ferrari, Mahila
    Pacifici, Monica
    Grana, Chiara M.
    Bartolomei, Mirco
    Baio, Silvia M.
    Sansovini, Maddalena
    Paganelli, Giovanni
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (10) : 1847 - 1856
  • [5] Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
    Bodei, Lisa
    Cremonesi, Marta
    Grana, Chiara M.
    Fazio, Nicola
    Iodice, Simona
    Baio, Silvia M.
    Bartolomei, Mirco
    Lombardo, Dario
    Ferrari, Mahila E.
    Sansovini, Maddalena
    Chinol, Marco
    Paganelli, Giovanni
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (12) : 2125 - 2135
  • [6] Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model
    Breeman, WAP
    Mearadji, A
    Capello, A
    Bernard, BF
    van Eijck, CHJ
    Krenning, EP
    de Jong, M
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (03) : 376 - 379
  • [7] 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
    Bushnell, David L., Jr.
    O'Dorisio, Thomas M.
    O'Dorisio, M. Sue
    Menda, Yusuf
    Hicks, Rodney J.
    Van Cutsem, Eric
    Baulieu, Jean-Louis
    Borson-Chazot, Francoise
    Anthony, Lowell
    Benson, Al B.
    Oberg, Kjell
    Grossman, Ashley B.
    Connolly, Mary
    Bouterfa, Hakim
    Li, Yong
    Kacena, Katherine A.
    LaFrance, Norman
    Pauwels, Stanislas A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) : 1652 - 1659
  • [8] Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
    Claringbold, Phillip G.
    Price, Richard A.
    Turner, J. Harvey
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2012, 27 (09) : 561 - 569
  • [9] Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
    Claringbold, Phillip G.
    Brayshaw, Paul A.
    Price, Richard A.
    Turner, J. Harvey
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (02) : 302 - 311
  • [10] Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study
    Cwikla, J. B.
    Sankowski, A.
    Seklecka, N.
    Buscombe, J. R.
    Nasierowska-Guttmejer, A.
    Jeziorski, K. G.
    Mikolajczak, R.
    Pawlak, D.
    Stepien, K.
    Walecki, J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (04) : 787 - 794
123456